This lack of antibody response can be attributed to the diagnosis of the PID patient (nude severe combined immunodeficiency) and the ongoing therapeutic regimen for the HSCT patient, which involves corticosteroid administration and anti-TNF therapy with adalimumab. The gene discussed is TNF; the disease is severe combined immunodeficiency.